Cancer Center

In this study, a team led by Gosse J. Adema, Ph.D., of the Department of Tumor Immunology, at the Radboud University Nijmegen Medical Centre, the Netherlands, and colleagues assessed the role of DC-SCRIPT as a co-regulator of nuclear receptors, including estrogen receptor (ER), progesterone receptor (PR)-B, peroxisome proliferator-activated receptor gamma, and retinoic acid receptor alpha. Prognostic value was assessed in three independent cohorts of breast cancer patients.

The researchers found that DC-SCRIPT suppressed ER- and PR-mediated transcription in a ligand-dependent fashion, whereas it enhanced the activity of the other two receptors. Quantification of DC-SCRIPT mRNA expression in the three cohorts of patients revealed that this expression is an independent prognostic factor for breast cancer patients with ER- and/or PR-positive tumors, according to the authors.

» Read more: DC-SCRIPT Found to Have Prognostic Value in Breast Cancer

Related posts

• Pancreatic Tumors Are Marked for Immunotherapy
• Breast Cancer: Women’s Killer
• CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer
• The Richardson Cancer Prevention Diet: A Nutrition and Diet Regimen for the Prevention of Cancer
• Poor ‘missing out on cancer care’